摘要
目的:观察用健脾益肾补气养血法指导的健脾益肾生血汤治疗晚期NSCLC患者血虚型癌性贫血的临床疗效。
方法:按随机对照的方法把符合课题研究的晚期NSCLC合并血虚型癌性贫血的患者分组,共收集试验组30例、对照组30例。两组依据病情做相同标准的辅助治疗。对照组用铁剂、叶酸、维生素B_12来改善贫血;试验组用铁剂、叶酸、维生素B_12的同时加用健脾益肾生血汤来改善贫血。治疗2个月,观察贫血指标血红蛋白值(Hb)的变化、中医血虚证侯的改善情况,人体功能状态KPS评分的变化。
结果:在Hb值方面,试验组改善56.67%,对照组改善23.33%,依据Ridit分析有统计学意义(p＜0.05),说明试验组在改善Hb值方面优于对照组。在中医血虚证侯积分方面,试验组改善63.33%,对照组改善20%,依据Ridit分析有统计学意义(p＜0.05),说明试验组在改善中医血虚证侯方面优于对照组。在KPS评分方面,试验组改善56.67%,对照组26.67%,依据Ridit分析有统计学意义(p＜0.05),说明治疗后试验组人体功能状态改善优于对照组。
结论:用健脾益肾补气养血法指导下的健脾益肾生血汤应用于晚期NSCLC患者血虚型癌性贫血,在提高Hb水平、改善中医血虚证侯、改善人体功能状态上,有明显的疗效。说明健脾益肾补气养血法在治疗血虚型癌性贫血方面具有显著疗效。
Objective: To observe the clinical efficacy of Jianpi Yishen Buqi Yangxue Tang,which is under the guidance of Jianpi Yishen Buqi Yangxue Method,in treating Xuexu tumor anemia patients with advanced-stage NSCLC.
Methods:Divided the Xuexu tumor anemia patients with advanced-stage NSCLC which met the demand.30 cases of test group and 30 cases of control group were collected.Both groups were treated with adjuvant therapy by the same standard.the control group used Iron, folic acid and vitamin B12 to improve anemia;the test group added Jian Pi Yi Shen Sheng Xue Tang.The time of treatment was 2 months.We observed the change situation of anemia indicator Hb and Chinese medicine symptoms of Xuexu,and the change of the body function KPS.
Results: In the change of Hb values, the test group had 56.67% improvement and the control group had 23.33% improvement There was a significant on Ridit Analysis (p<0.05),It is said that the test group is better than the control group by improving the Hb value; In the change of the scores of Xuexu symptoms,the test group had 63.33% improvement and the control group had 20% improvement. There was a significant on Ridit Analysis (p<0.05),It is said that the test group is better than the control group by improving the Xuexu symptoms;To observe the change situation of KPS,the test group was 56.67% improvement,and the control group was 26.67% improvement,There was a significant on Ridit Analysis (p<0.05),It was said that the test group's human functional state is better than the control group's after treatment.
Conclusion: The application of Jianpi Yishen Buqi Yangxue Method (Jianpi Yishen Shengxue tang) to tumor Xuexu anemia in patients with advanced NSCLC was effective.It can increase the Hb level and improve the symptoms of Xuexu .It also can improve the functional status of the human body.Jianpi Yishen Buqi Yangxue Method have good effect in treating Xuexu tumor anemia .
引文
[1]陈衍,刘文超,程婕.癌性贫血的最新临床研究进展.现代肿瘤学,2008,16(1):1995
[2]SCHWARTZ R N.Anemia in patients with cancer:incidence,causes,impact,management,and use of treatmentguidelines and protocols[J].Am JHealth-SystPharm,2007,64(1):S5-S13
[3]Glaspy J,Cavill I.Role of iron in optimizing responses of anemic cancer patients to erythropoietin[J].Oncology,1999,13(4):461-473
[4]Dalton JD,Bailey NP,Barrent-Lee PJ,O'BrienMER.MulticenterUK audit of anemia in patients receiving cytotoxic chemotherapy(abstract)[J].Proc ASCO,1998,17:418a
[5]Okamoto H,Saijo N,Shinkai T,et al.Chemotherapy-induced anemia in patients with primary lung cancer[J].Ann oncol,1992,3:819-24
[6]Wozniak A J,Crowley JJ,Balcerxak SP,et al.Randomized trail comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced NSCLC:a southwest Oncology Group study[J].J clinoncol,1998,16:2459-65
[7]Elis PA,Smith IE,Hardy JR,et al.Symptom relief with MVP(mitomycin c,vinblastine and cisplatin) chemotherapy in advanced NSCLC[J].Br J Cancer,1995,71:366-70
[8]Ludwig H,et a.l The European Cancer Anaemia Survey(ECAS):A large,multinationa,l prospective survey defi-ning the prevalence,incidence,and treatment of anaemia incancer patients.Eur J Cancer,2004,40(15):2293
[9]廖辉,等.586例肿瘤患者贫血发生率调查.癌症进展杂志,2007,5(6):582
[10]Caro JJ,SalasM,Ward A,et a.l Anemia as an independent prognostic factor for survival in patientswith cancer:A systemic,quantitative review[J].Cancer,2001,91(12):2214-2221
[11]GlaserCM,MillesiW,KornekGV,eta.l Impactofhemoglobin level and use of recombinant erythropoietin on efficacy of preop-erative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx[J].Int J RadiatOncol Biol Phys,2001,50(3):705-715
[12]GroganM,Thomas GM,Melamed I,et a.l The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix[J]. Cancer, 1999, 86(8): 1528-1536
[13]Ahlberg K, et al. Assessment and management of cancerrelated fatigue in adults. Lancet, 2003, 362 (9384) : 640
[14]LeeWR, BerkeyB, MarcialV, eta.l Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma:A secondary analysis of RTOG 85-27[J.IntJRadiatOncolBiolPhys, 1998,42(5): 1069-1075
[15]Maestu I, PastorM, Gomez-Codina J, et a.l Pretreatment prog-nostic factors for survival in small-cell lung cancer: A new prog-nostic index and validation of three known prognostic indices on341 patients[J]. Ann Onco,l 1997, 8(6): 547-553
[16]Moullet I, Salles G, KettererN, et a.l Frequency and signifi-cance of anemia in non-Hodgkin s lymphoma patients[ J]. Ann Onco,l 1998, 9(10): 1109-1115
[17]MunstedtK, KovacicM, ZygmuntM, et a.l Impactofhemoglo-bin levels before and during chemotherapy on survival ofpatients with ovarian cancer[J]. Int JOnco,l 2003, 23(3): 837-843.
[18]Shasha D. The negative impact of anemia on radiotherapy and chemoradiation outcomes[J]. SeminHemato,l 2001, 38(3 Sup-p17): 8-15
[19]PeterD, PaulS, Raimund J, eta.l Anemia is a significantprog-nostic factor in local relapse-free survival of premenopausal pri-mary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy [J].Clin Cancer Res, 2008, 14(7): 2082-2087
[20]Fein DA,LeeWR, Hanlon AL, et a.l Pretreatment hemoglobin level influences local controland survivalofT1-T2 squamous cell carcinomasof the glottic larynx[J]. JClinOnco,l 1995, 13(8):2077-2083
[21]Dubray B,Mosseri V,Brunin F,et a.l Anemia is associatedwith lower local-regional controland survivalafter radiation thera-py for head and neck cancer: a prospective study[J]. Radiolo-gy, 1996, 201(2): 553-558
[22]Warde P,O Sullivan B, BristowRG, eta.l T1 /T2 glottic cancermanaged by external beam radiotherapy:the influence of pre-treatmenthemoglobin on local control[J].IntJRadiatOncolBi-olPhys, 1998, 41(2): 347-353
[23]van AchtMJ,Hermans J,BoksDE,et a.l The prognostic value ofhemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma[J].Radiother Onco,l 1992,23(4):229-235
[24]TarnawskiR,SkladowskiK,MaciejewskiB.Prognostic value of hemoglobin concentration in radiotherapy for cancer of supraglot-tic larynx[J].Int J Radiat Oncol Biol Phys,1997,38(5):1007-1011
[25]KumarP.Impactofanemia in patientswith head and neck cancer[J].TheOncologist,2000,5(Suppl2):13-18
[26]GrantDG,Hussain A,Hurman D.Pre-treatment anemia alters outcome in early squamous cell carcinoma of the larynx treated by radical radiotherapy[J].JLaryngolOto,l 1999,113(9):829-833
[27]Shen JG,Cheong JH,HyungWJ,et a.l Pretreatment anemia isassociated with poorer survival in patientswith stage Ⅰ and Ⅱ gastric cancer[J].J SurOnco,l 2005,91(2):126-130
[28]Becker A,Starller P,Lavey,et al.Sever anermia is associated with poor tumoroxygenation in head and neck squamous cell car-cinoma[J].Int JRadiatOncolBiolPhys,2000,46:459-466
[29]Smaniotto D,Luzi S,Morganti AG,etal.Prognostic s ignificance of anemia and role of erythropoietin in radiation therapy[J].Tumori,2000,86(1):17-23
[30]Gunter Weiss.Iron and anemia of chronic disease.Kindey International,1999,55:512 s12-s17
[31]MolitemoAR,Spivak JK.anemia of cancer.Hematol Oncol Clin Nam,1996,10(2):345
[32]符晓阳,袁记,杨金华.胃肠道肿瘤患者围手术期输血与术后感染的关系[J].河北外科学杂志.2005,11(1):45
[33]张爱玲,工永霞,曹茵,等.围手术期输血对乳腺癌术后复发转移的影响[J].肿瘤防治杂志.2005,12(16):1259-1260
[34]胡阳,林嘉,崔彬.胃癌病人术前输血指征的探讨[J]中华腹部疾病杂志.2005.11(5):787-789
[35]程晶.伍钢.彭纲.等.重组人红细胞生成素治疗恶性肿瘤贫血的临床观察[J].肿瘤 防治杂志,2005,32(8):511-512
[36]姜永生.于世英.重组人促红细胞生成素在肿瘤相关性贫血中的应用[J],国新药杂志.2005,14(8):961-963
[37]Fisher JW.Erythropoietin:physiology and pharmacology update.Exp Biol Med,2003,228(1):1-14
[38]Storring PL,Tiiplady R J,Gaines Das RE,et al.Epoetin alpha and beta differ in their ervthropoiet in isoform compositions and biolo}ical properties[J].Br J Haematol,1998,100(1):79-89
[39]Olsson AM,Svensson JH,Sundstrom J,et al.Erythropoietin treatment in metastatic breast cancer-effects on Hb,quality of life and need for transfusion[J].Acta Oncol,2002,41(6):517-524
[40]Oberhoff C,Neri B,Amadori D,et al.Recombinant human erythropoietin in the treatment of chemotherapy-induced ane-mia and prevention of transfusion requirement associated with solid tomor:a randomized,controlled study[J].Ann Oncol,1998,9(3):255-260
[41]Littlewood TJ,Bajetta E,Nortier JW et a.l Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy:results of a randomized,double-blind,placebo-controlled trial[J].J Clin Onco,l 2001,19(11):2865-2874
[42]Crawford J,DemetriGD,Gabrilove JL,eta.l Clinical benefit sofepo-etin alfa therapy in patientswith lung cancer[J].Clin Lung Cancer,2002,3(3):180-190
[43]ShashaD,GeorgeMJ,Harrison LB Once-weekly dosing ofepoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequen-tiallywith chemotherapy[J].Cancer,2003,98(5):1072-1079
[44]Jacobsen P ThorsC,CawleyM,eta.l Relation ofdecline in hemoglo-bin to cognitive functioning and fatigue during chemotherapy treatment[J].ProcAm Soc Clin Onco,l 2002,21:386a
[45]LangerCJ,Hirsch FR,Cortes-FunesH,et a.l Targeted molecular mechanisms of epoetin alfa[J].Lung Cancer,2003,41 Suppl 1:S133-S145
[46]Osterborg A,Brandberg Y,Molostova V,et al.Randomized,double-blind,placebo-controlled trial of recombinant human erythropoietin,epoetin beta,in hematologic malignancies[J].JClin Oncol,2002,20(10):2486-2494
[47]Boogaerts M,Coiffier B,Kainz C.Impact of epoetin beta onquality of life in patients with malignant disease[J].Br J Cancer,2003,88(6):988-995
[48]Bohlius J,W ilson J,Seidenfeld J,eta.l Recombinanthuman erythropoietins and cancerpatients:updatedmeta-analysis of 57 studies including 9353 patients[J].J Natl Cancer Inst,2006,98(10):708-714
[49]Bohlius J,W ilson J,Seidenfeld J,eta.l Erythopoietin ordarbepoetin for patients with anemia[J].Cochrane Database Syste Rev,2006,3:CD003407
[50]BennettCL,CournoyerD,Carson KR,et a.l Long-term outcome of individualswith pure red cell aplasia and aniterythropoietin antibodies in patients treatedwith recombinantepoetin:a follow-up report from the Research on Adverse Drug Events and Reports(RADAR) Project[J].Blood,2005,106(10):3343-3347
[51]Osterborg A,Brandberg Y,Molostova V,et al.Randomized,double-blind,placebo-controlled trial of recombinant human erythropoietin,epoetin beta,in hematologic malignancies[J].JClin Oncol,2002,20(10):2486-2494
[52]Dunlop EA,Maxwell AP,Lappin TR.Imparied downregulation following erythropoietin activation in non-small cell lung caneer[J].Stem Cells,2007,25(2):380-384
[53]Caro JJ,Salas M,Ward A,et al.Anemia as an independent prognostic factor for survival in patients with cancer:A systematic,quantitative review.Cancer,2001,91:2-14
[54]高继良,沈壮虹.自拟生血汤治疗肿瘤化疗性贫血47例.中国中医药科技,2007,14(3):213-214
[55]刘永叶,谢晓冬,屈淑贤.自拟芪贞汤治疗肿瘤相关性贫血临床观察.深圳中西医结合杂志,2006,16(5):310-312
[56]张学民,钱钢,陈洁.自拟健脾补肾方治疗肿瘤相关性贫血疗效观察.江西中医药,2007,38(292):25-26
[57]胡欣.自拟补血汤治疗肿瘤相关性贫血的体会.辽宁中医杂志,2007,34(6):777-778
[58]孙伟芬,王惠杰,刘宪俊,黄伟贤.紫参汤治疗癌性贫血47例疗效观察.福建中医药 2000,31,(1):17-18
[59]张肖晗.中西医结合治疗肿瘤患者贫血的临床观察.四川中医,2007,25(5):54-55
[60]陆运鑫,罗昌国,黄丁平,陈小梅.温肾健脾补血法治疗肿瘤相关性贫血临床疗效观察.中国实用医药,2008,3(2):95-96
[61]潘迎英.健脾益肾法治疗癌性贫血36例.中医研究,2009,22(3):34-36
[62]陆崇,刘魁凤,曾小烈,等.补肾健脾化瘀法增强rHuEPO治疗肿瘤化疗后贫血疗效研究.现代生物医学进展,2007,7(12):1853-1855
[63]刘杰.健脾益肾颗粒治疗伴发贫血临床研究.北京中医药大学,博士研究生学位论文,2006:9-56
[64]田丽丽.益中生血胶囊治疗肿瘤相关性贫血的临床研究.北京中医药大学,博士研究生学位论文,2007:13-67
[65]Zuckerman KS.Hematopoietin abnormalities in patients with cancer[J].CancerControl,1998,5(2):6-11
[66]Sawaber Y,Takiguchi Y,Kikunok,et al.changes in terels of serum erythropoietin,serum iron and unsaturated iron binding capacity during chemotherapy for lung cancer[J].Jpn Jchin Oncel,1998,28(3):182-186
[67]徐景达.人参苷-Rh2的研究进展.人参研究.1996,(1):2-6
[68]王勇,祝彼得,王亚平.人参总皂试体外刺激小鼠造血作用机制的研究.中华血液学杂志.1995,16(12):648-649
[69]王亚平,王勇,姜蓉,等.人参总皂甙诱导造血生长因子生成的买验研兄.解剖学报.1997,28(3):304-308
[70]王璐,王亚平.人参总皂甙诱导人造血基质细胞表达IL3的实验研究.解剖学报.2004,35(1):49-54
[71]王浴生,邓文,薛春生.中药药理与应用第2版[M]北京:人民卫生出版社,2000:601-603
[72]夏丽英,何秀敏,王志海.阿胶与新阿胶对小鼠60Co照射所致造血损伤的治疗作用研究[J]中成药1992;14(1):30
[73]李宗铎.阿胶的药理作用[J]河南中医 1989;9(6):27
[74]程孝慈,吴中立,姚伟,等.阿胶对免血管通透性影响的实验观察[J]中药通报 1986;11(12):471
[75]李宗锋.阿胶的药理作用[J]中草药 1990;2(2):27
[76]王志海,吴斌,等.阿胶补血作用机理初探.山东中医杂志 1992,11(3):35
[77]夏丽英.阿胶对造血功能的药理作用[J]中成药 1992;14(1):30
[78]姜恩魁.升板胶对骨髓的影响(J)锦州医学院学报,1991;12(5):304
[79]秦玉龙.刘完素应用白术经验评析.江西中医药,2004,35(263):57-61
[80]黄宫绣.本草求真[M].上海:上海科学技术出版社,1979:7
[81]刘守真撰,孙治熙编校.河间医集·素问病机气宜保命集[M].北京:人民卫生出版社,1998:477
[82]张锡纯.医学衷中参西录·上册[M].石家庄:河北人民出版社 1974:308
[83]王好古.汤液本草·卷中·白术.四库全书·子部,文渊阁本
[84]孙喜才,张健,邱根全,等.白术抑瘤机理的探讨.陕西中医,1988,9(6):282
[85]孙喜才,张玉五,连文太,等.健脾益气方841-A对小鼠S180实体瘤增值的影响.陕西中医,1987,8(2):91
[86]焦新生,刘朝奇,朝莉,等.黄芪和白术对感染的色念珠菌的荷瘤鼠作用的实验.上海免疫学杂志,1995,15(5):313